Amylyx Pharmaceuticals, Inc. $AMLX Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

Posted by George Bondi on Sep 11th, 2026

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Free Report) by 10.4% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 173,407 shares of the company’s stock after buying an additional 16,318 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.16% of Amylyx Pharmaceuticals worth $3,114,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. BlackRock Inc. acquired a new position in Amylyx Pharmaceuticals during the second quarter worth about $158,534,000. Adage Capital Partners GP L.L.C. raised its holdings in Amylyx Pharmaceuticals by 54.5% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 8,800,000 shares of the company’s stock valued at $56,408,000 after acquiring an additional 3,102,395 shares during the last quarter. Perceptive Advisors LLC lifted its stake in Amylyx Pharmaceuticals by 0.4% in the 2nd quarter. Perceptive Advisors LLC now owns 7,902,365 shares of the company’s stock worth $50,654,000 after purchasing an additional 28,017 shares in the last quarter. TCG Crossover Management LLC lifted its stake in Amylyx Pharmaceuticals by 5.0% in the 3rd quarter. TCG Crossover Management LLC now owns 6,243,812 shares of the company’s stock worth $84,853,000 after purchasing an additional 300,000 shares in the last quarter. Finally, Vanguard Group Inc. boosted its holdings in shares of Amylyx Pharmaceuticals by 10.1% during the 4th quarter. Vanguard Group Inc. now owns 5,804,912 shares of the company’s stock worth $70,123,000 after purchasing an additional 531,162 shares during the last quarter. 95.84% of the stock is owned by hedge funds and other institutional investors.

Amylyx Pharmaceuticals Price Performance

Shares of NASDAQ AMLX opened at $32.09 on Friday. The company has a 50 day simple moving average of $25.43 and a 200-day simple moving average of $18.74. The company has a market capitalization of $3.58 billion, a P/E ratio of -22.44 and a beta of -0.13. Amylyx Pharmaceuticals, Inc. has a 1 year low of $10.83 and a 1 year high of $41.14.

Amylyx Pharmaceuticals (NASDAQ:AMLX – Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.03). As a group, research analysts expect that Amylyx Pharmaceuticals, Inc. will post -1.48 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the company. Guggenheim upped their price target on Amylyx Pharmaceuticals from $55.00 to $57.00 and gave the company a “buy” rating in a research report on Thursday, August 27th. Mizuho boosted their price objective on Amylyx Pharmaceuticals from $30.00 to $42.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 18th. Citigroup upped their target price on Amylyx Pharmaceuticals from $20.00 to $26.00 and gave the company a “buy” rating in a report on Monday, August 3rd. Wolfe Research raised Amylyx Pharmaceuticals to a “strong-buy” rating in a research note on Monday, August 17th. Finally, HC Wainwright lifted their price target on Amylyx Pharmaceuticals from $34.00 to $55.00 and gave the stock a “buy” rating in a report on Tuesday, August 18th. Two analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Amylyx Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $36.50.

Read Our Latest Research Report on AMLX

Insider Buying and Selling

In other news, insider Gina Mazzariello sold 15,000 shares of the company’s stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $18.32, for a total value of $274,800.00. Following the transaction, the insider owned 194,090 shares of the company’s stock, valued at $3,555,728.80. This represents a 7.17% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 10.90% of the stock is owned by corporate insiders.